<DOC>
	<DOCNO>NCT02330796</DOCNO>
	<brief_summary>A Phase IIA , open-label , multicenter , active-controlled , parallel-group clinical trial design evaluate safety efficacy two dos Bucillamine compare low-dose Colchicine treatment patient acute gout flare .</brief_summary>
	<brief_title>Bucillamine Treatment Acute Gout Flare Subjects With Moderate Severe Gout</brief_title>
	<detailed_description>To evaluate safety tolerability two regimen Bucillamine 100 mg ( 900 mg 1,800 mg ) seven day treatment compare Colchicine 0.6 mg ( 1.8 mg ) treatment patient acute gout flare</detailed_description>
	<mesh_term>Gout</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<mesh_term>Bucillamine</mesh_term>
	<criteria>Subjects must present confirmed diagnosis gout , meet American College Rheumatology ( ACR ) 1977 preliminary criterion classification acute arthritis primary gout Subjects must experience least one ( 1 ) acute gouty arthritic attack 12 month prior randomization Presence acute gout flare longer 3 day Visit 2 Pain intensity inclusion ( Visit 2 ) 710 11point PINRS ( define severe gout flare study ) All patient contraindication Colchicine use Subjects history intolerance NSAIDs ( Checklists Checklist 1 ) Subjects significant medical contraindication NSAIDs ( Checklist 2 ) Subjects past failure NSAIDs control acute gouty arthritis attack previous 12 month ( Checklist 3 ) Regarding significant medical contraindication NSAIDs past failure NSAIDs control acute gouty arthritis attack previous 12 month ( i.e . refractoriness NSAIDs ) patient must meet one criterion : 1 . At least one historical episode within previous 12 month refractory intolerant NSAIDs make physician concern use NSAIDs subsequent acute gout attack 2 . The current ( refer ) physician judgment NSAIDs appropriate treat patient 's gouty arthritis flare may due change patient status worsen comorbid condition comedications ( e.g. , GI tract disease , renal insufficiency , hypertension , fluid retention , concurrent use diuretic and/or angiotensin convert enzyme inhibitor angiotensin receptor blocker , especially CKD ) Subjects must willing able give write informed consent . A HIPAA and/or state privacy consent must also sign Subjects must able swallow tablet Use permit concomitant medication must unchanged dose frequency , 30 day prior screen Adequate organ function , evidence follow laboratory result within 90 day prior randomization ( historical lab result acceptable ) . Creatine clearance &gt; 45 mL/min base CockroftGault glomerular filtration rate ( GFR ) estimation For woman childbearing potential men partner childbearing potential , agreement use highly effective , nonhormonal form conception . Subjects rheumatoid arthritis , psoriatic arthritis , evidence/suspicion infectious/septic arthritis , acute polyarticular gout ( 4 joint ) , arthritis due cause gout may confound study assessment per Investigator discretion Subjects experience &gt; 2 acute gouty arthritic attack per month , &gt; 12 attack overall , 6 month prior randomization Subjects history myocardial infarction , unstable angina , cerebrovascular event , coronary artery bypass graft within previous 6 month prior screen Subjects Body Mass Index &gt; 45 kg/m2 ; calculate body weight ( kg ) /height ( ) 2 Screening Visit Subjects acute chronic infection include know HIV and/or Hepatitis B C Uncontrolled hypertension ( &gt; 160/90 mmHg seat ) ( first set BP assessment meet definition uncontrolled hypertension , second set BP assessment may perform patient rest least 30 min . If second set BP assessments meet definition uncontrolled hypertension patient eligible participation ) Subjects proteinuria ≥1+ ≥30 mg dipstick urinalysis confirm repeat assessment within 24 hour Subjects significant heart failure activity impairment ( Class IIIIV New York Heart Association ( NYHA ) Subjects history malignancy , 5 year prior randomization Subjects CKD NKF stag 3B 5 chronic renal dysfunction ( eGFR &lt; 45 mL/min/1.73m2 acc . Cockcroft Gault formula ) Subjects serious hepatic disorder ( ChildPugh score B C ) Subjects washed dopamine antagonist deplete drug exclude anticholinergic and/or antihistamine anticholinergic effect least 14 day prior Day 1 ( Visit 2 ) Subjects documented history alcohol substance abuse within 12 month prior randomization ( consumption &gt; 21 unit alcohol per week consider alcohol abuse ) Subjects significant CNS effect include vertigo dizziness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>